Phase 2 MMY2002 trial of daratumumab in patients with at least 3 lines of prior therapy or double refractory multiple myeloma | Dr María-Victoria Mateos at Annual Meeting 2015 - 101271

Spotlight
Video

Phase 2 MMY2002 trial of daratumumab in patients with at least 3 lines of prior therapy or double refractory multiple myeloma | Dr María-Victoria Mateos at Annual Meeting 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, María-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the results of the phase 2 MMY2002 trial of the anti-CD38 monoclonal antibody, daratumumab, in patients with at least 3 lines of prior therapy or double refractory multiple myeloma.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 06/22/15
Added : 3 years ago
Category : Multiple Myeloma